Sign inJoin waitlistJoin the waitlist

Mohamad Badawi

Associate Professor · Charleston Area Medical Center

Credentials: · · · · ·

History

Charleston Area Medical Center
Present
West Virginia University School of Medicine
Present

Pediatric Hematology/Oncology
Zucker School of Medicine at Hofstra/Northwell
2014–2017
Pediatrics
West Virginia University School of Medicine
2011–2014
Damascus University
2010–2011
Misr University for Science and Technology College of Medicine
2004–2008

Research

The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis
Pediatric Blood & Cancer · 2020 · 73 citations
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood Cancer
Oncology · 2022 · Last of 5 authors · 5 citations
Comparison of EMLA Cream versus Lidocaine Injection for Lumbar Puncture Pain Control in Pediatric Oncology Patients
Avicenna Journal of Medicine · 2022 · Last of 7 authors · 2 citations

Ashley Meyer
2 papers
AM
Alexa Magner
1 paper · 1 as a resident
AM
Andrea Merry-Sperry
1 paper
Anshul Vagrecha
1 paper · 1 as a fellow
Batool El Atoum
1 paper · 1 as a fellow
Daniel Cannone
1 paper · 1 as a fellow
Edward Nehus
1 paper
Elham Alqudah
1 paper · 1 as a resident
Gabriel Solorzano
1 paper · 1 as a resident
JL
Jeffrey Lipton
1 paper
Megha Suri
1 paper · 1 as a fellow
Rahiya Rehman
1 paper · 1 as a fellow

Clinical trials

Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures
Principal investigator · Completed · Phase 4
CAMC Health System
2019–2021
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2022–2030